Cepheid Eyes EUA from FDA for H1N1 Test | GenomeWeb

NEW YORK (GenomeWeb News) – A Cepheid official said yesterday that the firm expects to receive Emergency Use Authorization from the US Food and Drug Administration soon for the firm's molecular test for the 2009 influenza A H1N1 virus.

Cepheid CFO Andrew Miller said yesterday at the UBS Global Life Sciences Conference held here that the firm expects to file for full FDA clearance of the test after it receives the EUA. He said that the test will identify H1, H3, and novel H1N1 strains and will provide results in 45 minutes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.